N/A
Completed N=41
Asthma Controller Adherence After Hospitalization
Source: ClinicalTrials.gov NCT02615743 ↗Enrolled (actual)
41
Serious AEs
0.0%
Results posted
Jan 2018
Primary outcomePrimary: Comparison of Number and Percentage of Patients That Use Monitoring Device Over 30 Days (Feasibility) — 15; 17 Participants
Summary
This study sets out to assess whether daily text message reminders help to enhance the consistency of use of controller medications following hospitalization for pediatric asthma patients ages 4-11 and their families. Text message reminders will be delivered to a subject's cell phone for those in the intervention group and electronic monitors will placed on the controller inhalers at the time of hospital discharge to track medication use over time in both the intervention and the regular care group. Families will complete surveys on the day of enrollment (in person), day 30 (telephone) and day 60 (telephone) on aspects of asthma care including asthma knowledge, medication routines, who is responsible for asthma care, and medication beliefs.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Comparison of Number and Percentage of Patients That Use Monitoring Device Over 30 Days (Feasibility) |
15; 17 | — |
| PRIMARY Acceptability |
15; 5 | — |
| SECONDARY Adherence |
34; 40 | — |
| SECONDARY Change in Child Asthma Control Tool Score (cACT) From Baseline to End of Intervention Period. |
1.0; 3.1 | — |
Eligibility Criteria
Inclusion Criteria
- Has unlimited text messaging plan
- Prescribed one of the following metered dose inhalers for daily use: Flovent (fluticasone), QVAR (budesonide), Seretide (fluticasone-salmeterol), Advair multi-dose inhaler (MDI) (fluticasone-salmeterol) or Dulera (mometasone-formoterol)
- Patient receives primary care at one of the three urban CHOP primary care practices (Karabots, South Philadelphia, and Cobbs Creek)
Exclusion Criteria
- Subjects prescribed a controller medication to which the electronic device cannot affix (i.e. montelukast, Advair Diskus, Symbicort, Seretide Acuhaler/Diskus) as their primary controller medication
- Subjects with developmental delays or disabilities
- Families with active Department of Human Services (DHS) involvement
- Non-English speaking families
- Parents/guardians or subjects who the inpatient medical team recommends against approaching for enrollment in a research study
Data sourced from ClinicalTrials.gov (NCT02615743). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.